Study Title

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial

Study Details

Description:

The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.

Sponsor:

Clarity Pharmaceuticals

Contacts:

Clarity Pharmaceuticals (Clarity Clinical)

clinicaltrials@claritypharmaceuticals.com

+61 0 2 9209 4037

Government Study Link:

NCT04023331 - Click here to see study on

ClinicalTrials.gov

Inclusion

• Known high-risk neuroblastoma OR previously intermediate-risk neuroblastoma that has relapsed
• Karnofsky or Lansky performance status ≥50;
• Adequate liver function
• Adequate renal function

Exclusion

• Any other active malignancy, or a history of prior malignancy within the past 3 years;
• Participants with disease of any major organ system that would compromise their ability to tolerate therapy
• History of cardiac failure
• Participants who are on hemodialysis
• Any medical condition which the Investigator feels may interfere with the procedures or evaluations of the study

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

United States

University of Wisconsin

Madison, Wisconsin 53792, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.

Principal Investigator:

Medical University of South Carolina

Charleston, South Carolina 29425, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.

Principal Investigator:

Washington University School of Medicine

St. Louis, Missouri, United States

This badge indicates the Principal Investigator has a proven record of excellence in the advancement of Theranostics.

Principal Investigator: